menu
    • menu
    [{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"ALSA Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"AXV101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Axovia Therapeutics \/ ALSA Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ ALSA Ventures"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"AXV101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Axovia Therapeutics \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"AXV-101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Axovia Therapeutics \/ Axovia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ Axovia Therapeutics"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"AXV-101","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"AXV101","moa":"BBS1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"}]

    Find Clinical Drug Pipeline Developments & Deals by Axovia Therapeutics

    Menu

    Axovia Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AXV101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : A Race Against Blindness

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            A Race Against Blindness Announces $2 Million Grant to Support Sight-Saving Clinical Trial

                            Details : The funding aims to advance the clinical development of company's AXV101, which is aimed at combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1.

                            Product Name : AXV101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : AXV101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : A Race Against Blindness

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AXV-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : A Race Against Blindness

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            $1M Grant Supports Axovia's Bardet-Biedl Syndrome Clinical Trial

                            Details : The funding will be used to support the company’s lead program, AXV-101, an adeno-associated virus (AAV9)-based gene therapy targeting retinal dystrophy associated with Bardet-Biedl Syndrome.

                            Product Name : AXV-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 30, 2024

                            Lead Product(s) : AXV-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : A Race Against Blindness

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AXV-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Rhythm Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rhythm, Axovia Collaborate on Bardet-Biedl Syndrome Research

                            Details : The collaboration aims to advanced the clinical development of AXV-101, which is being evaluated in the early-stage clinical trial studies for the treatment of Bardet-Biedl syndrome.

                            Product Name : AXV-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 24, 2024

                            Lead Product(s) : AXV-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Rhythm Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AXV101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Recipient : Charles River Laboratories, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Charles River & Axovia Partner to Support Development of Gene Therapies for Ciliopathies

                            Details : The collaboration aims to support the development of Axovia’s gene therapies, including AXV101, for ciliopathies, including Bardet-Biedl Syndrome, a condition with limited options or no cure.

                            Product Name : AXV101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 09, 2024

                            Lead Product(s) : AXV101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Recipient : Charles River Laboratories, Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed

                            Axovia Therapeutics

                            United Kingdom arrow
                            33rd NZW-Hamburg
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AXV101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : ALSA Ventures

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ALSA Ventures Launches Novel Gene Therapy Portfolio Company Axovia Therapeutics to Treat Ciliopathies

                            Details : Axovia is developing the first gene therapies for ciliopathies and has a pipeline of products, including AXV101, an AAV9-based gene therapy targeting retinal dystrophy associated with BBS in patients carrying biallelic mutations in the BBS1 gene.

                            Product Name : AXV101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 19, 2023

                            Lead Product(s) : AXV101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : ALSA Ventures

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth